Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $823,848.16 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 53,083 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $15.52, for a total transaction of $823,848.16. Following the completion of the transaction, the chief executive officer owned 1,934,247 shares of the company’s stock, valued at $30,019,513.44. This trade represents a 2.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Adaptive Biotechnologies Price Performance

Adaptive Biotechnologies stock opened at $15.93 on Friday. Adaptive Biotechnologies Corporation has a 12-month low of $6.26 and a 12-month high of $20.76. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -39.82 and a beta of 2.19. The firm’s fifty day moving average price is $16.83 and its 200 day moving average price is $15.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same period last year, the firm earned ($0.23) earnings per share. The company’s revenue was up 51.0% on a year-over-year basis. Analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Key Headlines Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results and revenue beat — Adaptive reported stronger-than-expected Q4 results (EPS beat and revenue +51% YoY), which supports longer-term growth expectations and was a catalyst for bullish analyst notes earlier this quarter. MarketBeat ADPT page
• Positive Sentiment: Analyst backdrop mostly constructive — Multiple firms have buy/overweight ratings and recent price-target increases (consensus “Moderate Buy”), which provides support vs. headline volatility. Analyst coverage summary
• Neutral Sentiment: Short-interest data shows an anomalous 0-share reading and a 0.0 days-to-cover metric — this appears to be a data/reporting artifact rather than a meaningful change in bearish positioning. (No actionable signal until corrected data is posted.)
• Neutral Sentiment: Small institutional activity — several modest new or increased stakes were reported in recent filings; institutional ownership remains high (~99%). These moves are small relative to market cap and unlikely to drive intraday price action. Institutional holdings
• Negative Sentiment: Large CEO selling — CEO Chad Robins has executed multiple large sales, including a 289,024‑share sale on Mar. 2 at ~$15.82 (~$4.57M) and other recent disposals totaling hundreds of thousands of shares; these sizable reductions (one filing showed a ~12.7% position cut) are a near-term negative signal for investor sentiment. CEO sale SEC filing
• Negative Sentiment: Other insider sales — COO Julie Rubinstein sold ~30.9k shares (filings show sales at ~$15.67–$16.00 for ~$485k–$495k), and director/insider Harlan Robins sold multiple blocks (10k and ~14.2k shares). Multiple insider sales in a short window amplify market concern about near-term insider conviction. COO sale SEC filing Harlan sale SEC filing

Institutional Trading of Adaptive Biotechnologies

Several institutional investors have recently added to or reduced their stakes in ADPT. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after buying an additional 3,299,635 shares during the last quarter. Westfield Capital Management Co. LP acquired a new stake in Adaptive Biotechnologies during the fourth quarter worth about $65,942,000. Geode Capital Management LLC lifted its holdings in Adaptive Biotechnologies by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after acquiring an additional 110,825 shares during the last quarter. Finally, State Street Corp boosted its stake in Adaptive Biotechnologies by 3.3% in the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after acquiring an additional 102,362 shares during the period. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. BTIG Research upped their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target on the stock. Wall Street Zen upgraded shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.